Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ETNB
ETNB logo

ETNB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
741.82M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
848.24M
EV/OCF(TTM)
--
P/S(TTM)
--
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
Show More

Events Timeline

(ET)
2025-09-29
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-09-22 (ET)
2025-09-22
10:35:35
BTIG: Pfizer's Metsera Agreement Offers Positive Implications for Viking
select
2025-09-18 (ET)
2025-09-18
09:02:23
Video: Nvidia's Investment Boosts Intel's Power
select
link
2025-09-18
06:19:20
Roche Finalizes Merger Agreement to Acquire 89bio
select

News

Benzinga
4.0
2025-10-31Benzinga
Cantor Fitzgerald Halts Overweight Rating for 89bio
  • Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

  • Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.

  • Market Intelligence: Benzinga Pro aims to deliver the most accurate stock market intelligence, helping traders to capitalize on market opportunities.

PRnewswire
7.0
2025-10-16PRnewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating SWK Holdings Corporation, 89bio, Inc., Barinthus Biotherapeutics plc, and Verint Systems Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their recent transactions.

  • Shareholder Rights and Options: The law firm encourages shareholders of the mentioned companies to contact them for information on their legal rights and options, emphasizing that they operate on a contingent fee basis, meaning no upfront legal fees are required.

Globenewswire
7.0
2025-10-16Globenewswire
BRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations for 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
  • Investigation Announcements: Brodsky & Smith is reminding investors about ongoing investigations into several companies, including 89bio, Barinthus Biotherapeutics, Dayforce, and Verint Systems, regarding potential breaches of fiduciary duties by their boards during merger agreements.

  • Merger Details and Concerns: Each company is involved in a merger where the deal terms are being scrutinized for fairness, with specific concerns raised about whether the offered prices reflect fair value for shareholders, particularly in relation to recent stock performance highs.

Globenewswire
7.0
2025-10-08Globenewswire
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes DAY, BRNS, ETNB, VRNT for Shareholder Interests
  • Investigation of Companies: Halper Sadeh LLC is investigating Dayforce, Barinthus Biotherapeutics, 89bio, and Verint Systems for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.

  • Shareholder Rights: The law firm encourages shareholders of the mentioned companies to contact them for information on their legal rights and options regarding the proposed sales and mergers, with services offered on a contingent fee basis.

Globenewswire
7.0
2025-10-08Globenewswire
BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
  • Investigation Announcements: Brodsky & Smith is reminding investors about ongoing investigations into several companies, including 89bio, Barinthus Biotherapeutics, Dayforce, and Verint Systems, regarding potential breaches of fiduciary duties by their boards during merger agreements.

  • Merger Details and Concerns: Each company is involved in a merger where the deal terms are being scrutinized for fairness, with specific concerns raised about whether the offered prices reflect fair value for shareholders, particularly in relation to recent stock performance highs.

PRnewswire
7.0
2025-10-07PRnewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating several companies, including 89bio, Tourmaline Bio, Core Scientific, and Barinthus Biotherapeutics, for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their proposed sales and mergers.

  • Shareholder Rights and Legal Options: The firm encourages shareholders from these companies to explore their legal rights and options, offering to handle cases on a contingent fee basis, meaning no upfront legal fees are required from the shareholders.

Wall Street analysts forecast ETNB stock price to rise
6 Analyst Rating
Wall Street analysts forecast ETNB stock price to rise
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
11.00
Averages
28.33
High
55.00
Current: 0.000
sliders
Low
11.00
Averages
28.33
High
55.00
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
$32
AI Analysis
2025-09-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$32
AI Analysis
2025-09-19
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded 89bio (ETNB) to Neutral from Buy with a price target of $14.50, down from $32, after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash.
Raymond James
Outperform -> Market Perform
downgrade
2025-09-19
Reason
Raymond James
Price Target
2025-09-19
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded 89bio (ETNB) to Market Perform from Outperform without a price target after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash and an aggregate of $6 per share for three non-tradeable contingent value rights. While the deal is under Raymond James' previous $50 target, it is a positive development, the analyst tells investors in a research note. The firm estimates the deal could close by the end of 2025.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ETNB
Unlock Now

Valuation Metrics

The current forward P/E ratio for 89Bio Inc (ETNB.O) is -3.58, compared to its 5-year average forward P/E of -4.24. For a more detailed relative valuation and DCF analysis to assess 89Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.24
Current PE
-3.58
Overvalued PE
-2.02
Undervalued PE
-6.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.99
Current EV/EBITDA
-2.85
Overvalued EV/EBITDA
-0.37
Undervalued EV/EBITDA
-3.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
531.72
Current PS
0.00
Overvalued PS
1658.59
Undervalued PS
-595.16

Financials

AI Analysis
Annual
Quarterly

Whales Holding ETNB

E
Emerald Advisers, LLC
Holding
ETNB
+6.26%
3M Return
V
Vivo Capital, LLC
Holding
ETNB
+6.01%
3M Return
R
RA Capital Management, L.P.
Holding
ETNB
-5.03%
3M Return
A
Avoro Capital Advisors LLC
Holding
ETNB
-9.67%
3M Return
S
Suvretta Capital Management, LLC
Holding
ETNB
-10.41%
3M Return
D
Deep Track Capital, LP
Holding
ETNB
-14.30%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is 89Bio Inc (ETNB) stock price today?

The current price of ETNB is 0 USD — it has increased 0

What is 89Bio Inc (ETNB)'s business?

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.

What is the price predicton of ETNB Stock?

Wall Street analysts forecast ETNB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETNB is28.33 USD with a low forecast of 11.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is 89Bio Inc (ETNB)'s revenue for the last quarter?

89Bio Inc revenue for the last quarter amounts to -75.91M USD, increased 32.53

What is 89Bio Inc (ETNB)'s earnings per share (EPS) for the last quarter?

89Bio Inc. EPS for the last quarter amounts to -71809000.00 USD, increased 80.79

How many employees does 89Bio Inc (ETNB). have?

89Bio Inc (ETNB) has 93 emplpoyees as of March 25 2026.

What is 89Bio Inc (ETNB) market cap?

Today ETNB has the market capitalization of 741.82M USD.